Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma

Chun-Te Ho; Hung-Sheng Shang; Jin-Biou Chang; Jun-Jen Liu; Tsan-Zon Liu

doi:10.18632/oncotarget.4422

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma

Chun-Te Ho _, Hung-Sheng Shang, Jin-Biou Chang, Jun-Jen Liu and Tsan-Zon Liu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:26104-26118. https://doi.org/10.18632/oncotarget.4422

Metrics: PDF 1550 views | HTML 2000 views | ?

Abstract

Chun-Te Ho1,*, Hung-Sheng Shang2,*, Jin-Biou Chang2,*, Jun-Jen Liu3, Tsan-Zon Liu4

1Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan

2Department of Pathology, National Defense Medical Center, Division of Clinical Pathology, Tri-Service General Hospital, Taipei, Taiwan

3School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan

4Translational Research Laboratory, Cancer Center, Taipei Medical University and Hospital, Taipei, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Tsan-Zon Liu, e-mail: [email protected]

Jun-Jen Liu, e-mail: [email protected]

Keywords: chemotherapy, folate, GRP78, multi-drug resistance, hepatoma

Received: February 22, 2015 Accepted: June 17, 2015 Published: June 27, 2015

ABSTRACT

Patients with hepatocellular carcinoma (HCC) are prone to folate deficiency (FD). Here we showed that, in cell line-specific manner, FD caused resistance to FD-induced oxidative stress and multi-drug resistance (MDR). This resistance was due to upregulation of glucose-regulated protein 78 (GRP78) and Survivin. Using siRNA and Epigallocatechin gallate (EGCG), we found that GRP78 and Survivin cooperatively conferred MDR by decreasing FD-induced ROS generation. Our data showed that FD increases GRP78 and Survivin, which serve as ROS inhibitors, causing MDR in HCC. We suggest that folate supplementation may enhance the efficacy of chemotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4422

Publication Alerts

Research Papers:

Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma

Abstract